What is Kite Pharma?
Founded in 2009 and headquartered in Santa Monica, California, Kite Pharma specializes in developing cell therapy to treat and potentially cure cancer. The company's unique approach involves reengineering a patient's own immune cells to target and destroy cancer cells, focusing primarily on hematologic malignancies. Kite Pharma operates state-of-the-art cell therapy manufacturing facilities across California, Maryland, and the Netherlands, positioning itself as a leader in the rapidly evolving field of cancer immunotherapy. The company's commitment extends to ensuring these advanced treatments are available to eligible patients, driving forward the accessibility of cutting-edge oncology solutions.
How much funding has Kite Pharma raised?
Kite Pharma has raised a total of $225M across 4 funding rounds:
Private Equity
$12.5M
Series A
$35M
Debt
$50M
Stock Offering
$127.5M
Private Equity (2011): $12.5M, investors not publicly disclosed
Series A (2013): $35M led by David Bonderman, Michael Milken, Arie Belldegrun, Commercial Street Capital, Alta Partners, and Pontifax Ltd.
Debt (2014): $50M, investors not publicly disclosed
Stock Issuance/Offering (2014): $127.5M, investors not publicly disclosed
Key Investors in Kite Pharma
Alta Partners
Alta Partners is a venture capital firm with a strong focus on the healthcare and life sciences sectors, investing in companies that aim to revolutionize patient care and outcomes. They are known for supporting innovative biopharmaceutical and healthcare technology ventures.
Pontifax Ltd.
Pontifax Venture Capital is a life sciences-focused investment firm that backs transformative healthcare technologies from early research to late-stage development. They actively build and guide companies in the biopharmaceutical space.
What's next for Kite Pharma?
With its significant enterprise-level backing and a recent strategic investment, Kite Pharma is poised for continued expansion and advancement in the cell therapy market. The capital infusion will likely fuel further research and development, enhance manufacturing capabilities, and support the commercialization efforts for its pipeline of engineered T cell therapies. Kite Pharma's strategic focus on addressing unmet needs in cancer treatment, particularly in hematologic malignancies, positions it for sustained growth and impact in the biopharmaceutical sector. The company's trajectory suggests a strong emphasis on scaling operations and broadening market reach for its innovative cancer immunotherapies.
See full Kite Pharma company page
